Lightrock Netherlands B.V. Purchases 25,465 Shares of Encompass Health Corporation (NYSE:EHC)

Lightrock Netherlands B.V. increased its position in Encompass Health Corporation (NYSE:EHC - Free Report) by 32.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 103,006 shares of the company's stock after purchasing an additional 25,465 shares during the quarter. Encompass Health makes up about 2.8% of Lightrock Netherlands B.V.'s investment portfolio, making the stock its 16th largest holding. Lightrock Netherlands B.V. owned about 0.10% of Encompass Health worth $10,450,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Colonial Trust Co SC purchased a new position in shares of Encompass Health in the 4th quarter valued at approximately $29,000. Transce3nd LLC purchased a new position in shares of Encompass Health in the 4th quarter valued at approximately $40,000. CBIZ Investment Advisory Services LLC lifted its stake in shares of Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock valued at $42,000 after purchasing an additional 127 shares during the period. Signaturefd LLC lifted its stake in shares of Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company's stock valued at $65,000 after purchasing an additional 125 shares during the period. Finally, Arlington Trust Co LLC lifted its stake in shares of Encompass Health by 22.9% in the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 97.25% of the company's stock.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, EVP John Patrick Darby sold 10,000 shares of the business's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president owned 79,710 shares of the company's stock, valued at approximately $9,149,910.90. The trade was a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Mark J. Tarr sold 118,384 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total value of $14,387,207.52. Following the sale, the chief executive officer directly owned 527,070 shares of the company's stock, valued at $64,054,817.10. This represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 132,663 shares of company stock valued at $16,034,082. Company insiders own 2.10% of the company's stock.

Encompass Health Stock Performance

Encompass Health stock traded up $0.26 during mid-day trading on Monday, reaching $119.30. 368,505 shares of the stock traded hands, compared to its average volume of 701,410. The stock has a market capitalization of $12.02 billion, a PE ratio of 24.65, a price-to-earnings-growth ratio of 2.42 and a beta of 0.88. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.06 and a quick ratio of 1.06. Encompass Health Corporation has a 12-month low of $82.74 and a 12-month high of $123.13. The business's 50-day moving average is $119.39 and its 200-day moving average is $105.53.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter in the prior year, the business earned $1.12 earnings per share. Encompass Health's revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, sell-side analysts predict that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio is presently 14.05%.

Analyst Ratings Changes

A number of research analysts have issued reports on EHC shares. KeyCorp lifted their price objective on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. Barclays lifted their price objective on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Wall Street Zen cut Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Truist Financial reiterated a "buy" rating and set a $135.00 price objective (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Finally, Royal Bank Of Canada boosted their price target on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Encompass Health currently has an average rating of "Buy" and a consensus price target of $127.00.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.